HIGHLIGHTS
- who: April and colleagues from the University Hospital Magdeburg, Germany have published the paper: Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagli fl ozin: new insights coming from diabetes for its potential implications in other metabolic disorders, in the Journal: (JOURNAL)
- what: Since majority of the studies focused on the effect of empagliflozin on neutrophil dysfunction and inflammatory bowel disease and lack of a long-term follow-up, the current data were scant to evaluate the effect of empagliflozin on the liver, kidney and CV disease in GSDIb . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.